A 3-year follow-up study of 126 squamous cell carcinoma of the head and neck (SCCHN) patients receiving anti-PD-1/L1 therapy demonstrated that SMARCA4 mutation and/or frameshift were more frequently observed in responders than non-responders67. This evidence concerns the gene SMARCA4 and head and neck squamous cell carcinoma.